Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer.
作者： Isabell Witzel , Klaus Pantel , Rainer Neumann , Volkmar Müller , Fritz Jänicke
DOI:
关键词:
摘要: Background: A soluble fragment of the epidermal growth factor receptor (EGFR) extracellular domain (sEGFR) can be detected in serum cancer patients, but role sEGFR is still unclear. Materials and Methods: Blood samples from patients receiving chemotherapy for metastatic breast were collected before (n=101) after 3 courses therapy (n=39). Levels HER-2/neu (ECD) determined by standardized ELISA. Results: higher percentage (15%) showed values below 45ng/mL compared with control subjects (3%, p 15 ng/mL) also a shorter overall survival than those normal both parameters (7.1 versus 15.4 months, p=0.03). Again, this difference was estrogen receptor-positive tumors (4.6 month, p<0.0001). During treatment, decrease levels occurred 74.4% (p=0.014). Conclusion: Low are associated survival, particularly tumors. Chemotherapy frequently
mendeley.com参考文章(34)
Mitch Dowsett, Stephen R. D. Johnston, Sunil Pancholi, Simone Detre, Ian E. Smith, Lesley-Ann Martin, Julia Head, Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer. Clinical Cancer Research. ,vol. 9, ,(2003)
Ann S. Knoop, Søren M. Bentzen, Mette M. Nielsen, Birgitte B. Rasmussen, Carsten Rose, Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. Journal of Clinical Oncology. ,vol. 19, pp. 3376- 3384 ,(2001) , 10.1200/JCO.2001.19.14.3376
Yosef Yarden, Mark X. Sliwkowski, Untangling the ErbB signalling network Nature Reviews Molecular Cell Biology. ,vol. 2, pp. 127- 137 ,(2001) , 10.1038/35052073
C. L. Arteaga, EGF receptor as a therapeutic target: patient selection and mechanisms of resistance to receptor-targeted drugs. Journal of Clinical Oncology. ,vol. 21, ,(2003) , 10.1200/JCO.2003.10.523
A. Lipton, S.M. Ali, K. Leitzel, L. Demers, H.A. Harvey, H.A. Chaudri-Ross, C. Brady, P. Wyld, W. Carney, Serum HER-2/neu and Response to the Aromatase Inhibitor Letrozole Versus Tamoxifen Journal of Clinical Oncology. ,vol. 21, pp. 1967- 1972 ,(2003) , 10.1200/JCO.2003.09.098
Iain R. Hutcheson, Janice M. Knowlden, Tracie-Ann Madden, Denise Barrow, Julia M.W. Gee, Alan E. Wakeling, Robert I. Nicholson, Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Research and Treatment. ,vol. 81, pp. 81- 93 ,(2003) , 10.1023/A:1025484908380
Volkmar Müller, Isabell Witzel, Hans Joachim Lück, Günter Köhler, Gunther von Minckwitz, Volker Möbus, Daniel Sattler, Waldemar Wilczak, Thomas Löning, Fritz Jänicke, Klaus Pantel, Christoph Thomssen, Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer. Breast Cancer Research and Treatment. ,vol. 86, pp. 9- 18 ,(2004) , 10.1023/B:BREA.0000032919.83803.48
Hidefumi Sasaki, Haruhiro Yukiue, Atsushi Sekimura, Kotaro Mizuno, Akimitsu Konishi, Motoki Yano, Ichiro Fukai, Yoshitaka Fujii, Elevated serum epidermal growth factor receptor level in stage IV thymoma. Surgery Today. ,vol. 34, pp. 477- 479 ,(2004) , 10.1007/S00595-003-2722-0
W Jacot, J-L Pujol, J-M Boher, P-J Lamy, Serum EGF-receptor and HER-2 extracellular domains and prognosis of non-small-cell lung cancer. British Journal of Cancer. ,vol. 91, pp. 430- 433 ,(2004) , 10.1038/SJ.BJC.6601987
J. M. W. Gee, M. E. Harper, I. R. Hutcheson, T. A. Madden, D. Barrow, J. M. Knowlden, R. A. McClelland, N. Jordan, A. E. Wakeling, R. I. Nicholson, The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology. ,vol. 144, pp. 5105- 5117 ,(2003) , 10.1210/EN.2003-0705